All News - Eli Lilly and Company
WEBRecent Press Releases. View All Press Releases. FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe …
Press Releases - Eli Lilly and Company
WEBSep 13, 2024 · Press Releases. ALL CORPORATE FINANCIAL PRODUCT IMPACT ARCHIVE. New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis. September 25, 2024.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8, 2023 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the …
WEB5 days ago · The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Alzheimer's drug donanemab shows positive results, Eli Lilly ... - CNBC
WEBJul 17, 2023 · Eli Lilly is among the pharmaceutical companies racing to market new treatments for the disease after Eisai and Biogen's drug Leqembi won FDA approval this month. The agency's signoff on Leqembi...
Eli Lilly (LLY) earnings Q2 2024 - CNBC
WEBAug 8, 2024 · The success of Eli Lilly's weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
News Release - Eli Lilly and Company
WEBOct 6, 2022 · The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
New Manufacturing Investments | Eli Lilly and Company
WEBIn Concord, Lilly plans to invest $1 billion to create a new injectable products and devices manufacturing site, along with nearly 600 jobs. Additionally, the company plans to invest $500 million in Limerick to create a new biologics …
Lilly to Acquire POINT Biopharma to Expand Oncology …
WEBOct 3, 2023 · Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion) payable at closing.
Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Disease
WEBMay 3, 2023 · The drug manufacturer Eli Lilly announced on Wednesday that a clinical trial of an experimental Alzheimer’s drug showed it can slow progress of the feared disease and allow patients to have...